PER-021-09已完成未知
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- PFIZER S.A.,
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •The patient must give written consent to participate in the study, signing and dating an informed consent document indicating that the patient has been informed of all relevant aspects of the study, before any procedure related to the study is performed. .
- •The patient who meets the eligibility criteria to, and be randomized and treated intravenously with Study drug A4091003.
- •At least 8 weeks, but not more than 16, must have elapsed since the intravenous infusion of the study drug of A4091003.
- •Female patients must meet one of the following criteria: a) Female patients without pregnancy potential: they must be post menopausal, defined as women who are> 45 years of age, amenorrheic for more than 24 consecutive months (regardless of levels of FSH in Study Selection A4091003), or women who are amenorrheic for at least 1 year AND have a serum follicle stimulating hormone (FSH) level, which is greater than 30 lU / L in the Selection of Study A4091003; or have been surgically sterilized, this is defined as having performed a hysterectomy and / or a bilateral oophorectomy. b) Female patients with potential for pregnancy: they must not be pregnant or breastfeeding and must practice withdrawal or use appropriate contraceptive methods (2 forms of contraceptive control, one of which must be a barrier method) from the Baseline visit until 16 weeks later of the last dose of the study medication. Women with pregnancy potential must have a negative result in the serum pregnancy test at the Study End Visit A4091003, or a negative result in the urine pregnancy test at the Baseline, before the initial dosage.
- •Patients must have obtained a Karnofsky Performance score> 40% at Baseline;
- •The patient has a life expectancy> 6 months at the Baseline;
- •The patient must desire and be able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
排除标准
- •The patient was removed from Study A4091003 because of an adverse event or a serious adverse event.
- •Use of any investigational medication within 30 days prior to Baseline, or plans to receive an investigational medication other than the study medication, during the course of this study.
- •Patients who were suspended in Study A4091003 before Week 8 due to lack of compliance with the treatment, violation of the protocol, failure to meet the inclusion criteria, revocation of consent, disease progression, or patients who were lost during the follow-up they will be excluded from the Study
- •Appearance of any adverse event or condition, during Study A4091003 or since the termination of that study, which in the opinion of the investigator, would put the patient at an increased safety risk, or that would exclude him from participating in the open extension.
研究者
相似试验
已完成
2 期
A Open label extension study of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To BoneCTRI/2011/09/002007Pfizer Limited58
进行中（未招募）
不适用
PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASESPAIN DUE TO BONE METASTASESMedDRA version: 13.1Level: LLTClassification code 10049038Term: Metastatic bone painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005182-66-ATPfizer Inc 235 East 42nd Street New York, NY 1001758
进行中（未招募）
不适用
PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASESPAIN DUE TO BONE METASTASESMedDRA version: 9.1Level: LLTClassification code 10049038Term: Metastatic bone painEUCTR2008-005182-66-LVPfizer Inc 235 East 42nd Street New York, NY 1001758
进行中（未招募）
1 期
PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASESPAIN DUE TO BONE METASTASESMedDRA version: 9.1Level: LLTClassification code 10049038Term: Metastatic bone painEUCTR2008-005182-66-FRPfizer Inc 235 East 42nd Street New York, NY 1001758
进行中（未招募）
1 期
PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASESPAIN DUE TO BONE METASTASESMedDRA version: 9.1Level: LLTClassification code 10049038Term: Metastatic bone painEUCTR2008-005182-66-HUPfizer Inc 235 East 42nd Street New York, NY 1001760